Follow-up
| . | 2 mg (N = 35) . | 4 mg (N = 35) . |
|---|---|---|
| Progression status | ||
| No progression | 9 (25.7%) | 10 (28.6%) |
| Progression | 26 (74.3%) | 25 (71.4%) |
| Follow-up status | ||
| Alive | 25 (71.4%) | 24 (68.6%) |
| Dead | 10 (28.6%) | 11 (31.4%) |
| Median follow-up, alive patients, mo (range) | 9.7 (1.0-17.7) | 6.6 (1.2-11.3) |
| Median no. of cycles administered per patient (range) | 6.0 (1.0-17.0) | 3.0 (1.0-12.0) |
| Currently receiving treatment | 5 (14%) | 4 (11%) |
| Reason for ending treatment | ||
| Refused further treatment | 1 (3.3%) | 1 (3.2%) |
| Adverse event | 1 (3.3%) | 3 (9.7%) |
| Disease progression | 25 (83.3%) | 21 (67.7%) |
| Alternate treatment | 0 (0%) | 2 (6.5%) |
| Other medical problems | 0 (0%) | 2 (6.5%) |
| Died on study | 2 (6.7%) | 2 (6.5%) |
| Other | 1 (3.3%) | 0 (0%) |
| . | 2 mg (N = 35) . | 4 mg (N = 35) . |
|---|---|---|
| Progression status | ||
| No progression | 9 (25.7%) | 10 (28.6%) |
| Progression | 26 (74.3%) | 25 (71.4%) |
| Follow-up status | ||
| Alive | 25 (71.4%) | 24 (68.6%) |
| Dead | 10 (28.6%) | 11 (31.4%) |
| Median follow-up, alive patients, mo (range) | 9.7 (1.0-17.7) | 6.6 (1.2-11.3) |
| Median no. of cycles administered per patient (range) | 6.0 (1.0-17.0) | 3.0 (1.0-12.0) |
| Currently receiving treatment | 5 (14%) | 4 (11%) |
| Reason for ending treatment | ||
| Refused further treatment | 1 (3.3%) | 1 (3.2%) |
| Adverse event | 1 (3.3%) | 3 (9.7%) |
| Disease progression | 25 (83.3%) | 21 (67.7%) |
| Alternate treatment | 0 (0%) | 2 (6.5%) |
| Other medical problems | 0 (0%) | 2 (6.5%) |
| Died on study | 2 (6.7%) | 2 (6.5%) |
| Other | 1 (3.3%) | 0 (0%) |